David Fajgenbaum is battling a little-known, extremely deadly disease as a researcher, a physician, an advocate, an entrepreneur and a patient.
Could health gains from the ACA be in jeopardy from reluctance to continue state-based Medicaid payments? A Wharton Health Care Management alum sounds off.
Dr. David Fajgenbaum is taking on a rare and deadly disease, Castleman, to save lives, using all the entrepreneurial and health care tools at his disposal.
The Penn Wharton Public Policy Initiative showcased two of Wharton’s pre-eminent health care minds to discuss upcoming implementations of the Affordable Care Act.